Crossmark

Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites

Crossref DOI link: https://doi.org/10.1186/s12885-022-09336-3

Published Online: 2022-02-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yokomichi, Naosuke

Imai, Kengo

Sakamoto, Masaki

Horiki, Masashi

Yamauchi, Toshihiro

Miwa, Satoru

Inoue, Satoshi

Uneno, Yu

Suzuki, Hidekazu

Wada, Toru

Ichikawa, Yuri

Morita, Tatsuya
Funding

Funding for this research was provided by:

JSPS KAKENHI (JP20K16567)
License Information

Text and Data Mining valid from 2022-02-28

Version of Record valid from 2022-02-28
More Information

Article History

Received: 29 September 2021

Accepted: 25 January 2022

First Online: 28 February 2022

Declarations

:

: The study was performed in accordance with the ethical standards of the Helsinki Declaration and the ethical guidelines for epidemiologic research of the Ministry of Health, Labour and Welfare of Japan. The protocol, procedures, information sheets, consent forms, and questionnaires were approved by the Institutional Review Board of Seirei Mikatahara General Hospital (review number: 17–61). Patients gave written informed consent before enrollment.

: Not applicable.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below